GDC-6036 - new drug for KRAS G12C+ cancers looking promising in preclinical studies

GDC-6036 - new drug for KRAS G12C+ cancers looking promising in preclinical studies. More potent than sotorasib & adagrasib. Clinical trial will be crucial in determining applicability in clinical setting/treatment sequencing for KRAS pG12C+ tumors

https://www.lungevity.org/